In vivo regulation of HIV-1 long terminal repeat by UV light and various skin applicants in transgenic mice
Document Type
Article
Journal/Book Title/Conference
Journal of Acquired Immune Deficiency Syndromes
Volume
4
Publication Date
1991
First Page
328
Last Page
329
Abstract
UV irradiation has been shown to activate the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in cell culture; however, only limited studies have been described in vivo. UV light has been categorized as UV-A (400 to 315 nm), -B (315 to 280 nm), or -C (less than 280 nm); the longer wavelengths are less harmful but more penetrative. Highly penetrative UV-A radiation constitutes the vast majority of UV sunlight reaching the earth's surface but is normally harmless. UV-B irradiation is more harmful but less prevalent than UV-A. In this report, the HIV-1 LTR-luciferase gene in the skin of transgenic mice was markedly activated when exposed to UV-B irradiation. The LTR in the skin of transgenic mice pretreated topically with a photosensitizing agent (psoralen) was also activated to similar levels when exposed to UV-A light. A 2-h exposure to sunlight activated the LTR in skin treated with psoralen, whereas the LTR in skin not treated with psoralen was activated after 7 h of sunlight exposure. The HIV-1 LTR-beta-galactosidase reporter gene was preferentially activated by UV-B irradiation in a small population of epidermal cells. The transgenic mouse models carrying HIV-1 LTR-luciferase and LTR-beta-galactosidase reporter genes have been used to demonstrate the in vivo UV-induced activation of the LTR and might be used to evaluate other environmental factors or pharmacologic substances that might potentially activate the HIV-1 LTR in vivo.
Recommended Citation
Morrey, J. D., S. M. Bourn, T. D. Bunch, R. W. Sidwell, L. R. Barrows, R. A. Daynes, and C. A. Rosen. 1991. In vivo regulation of HIV-1 long terminal repeat by UV light and various skin applicants in transgenic mice. Journal of Acquired Immune Deficiency Syndromes 4:328-329.